MX362517B - Forma cristalina de un inhibidor de transcriptasa inversa. - Google Patents

Forma cristalina de un inhibidor de transcriptasa inversa.

Info

Publication number
MX362517B
MX362517B MX2015003767A MX2015003767A MX362517B MX 362517 B MX362517 B MX 362517B MX 2015003767 A MX2015003767 A MX 2015003767A MX 2015003767 A MX2015003767 A MX 2015003767A MX 362517 B MX362517 B MX 362517B
Authority
MX
Mexico
Prior art keywords
hiv
aids
crystalline form
oxo
methyl
Prior art date
Application number
MX2015003767A
Other languages
English (en)
Spanish (es)
Other versions
MX2015003767A (es
Inventor
Courtney K Maguire
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2015003767A publication Critical patent/MX2015003767A/es
Publication of MX362517B publication Critical patent/MX362517B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2015003767A 2012-09-26 2013-09-20 Forma cristalina de un inhibidor de transcriptasa inversa. MX362517B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261705780P 2012-09-26 2012-09-26
PCT/US2013/060787 WO2014052171A1 (en) 2012-09-26 2013-09-20 Crystalline form of a reverse transcriptase inhibitor

Publications (2)

Publication Number Publication Date
MX2015003767A MX2015003767A (es) 2015-07-14
MX362517B true MX362517B (es) 2019-01-21

Family

ID=50388877

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003767A MX362517B (es) 2012-09-26 2013-09-20 Forma cristalina de un inhibidor de transcriptasa inversa.

Country Status (9)

Country Link
US (1) US9150539B2 (cg-RX-API-DMAC7.html)
EP (1) EP2900240B1 (cg-RX-API-DMAC7.html)
JP (2) JP6387349B2 (cg-RX-API-DMAC7.html)
CN (2) CN104684557A (cg-RX-API-DMAC7.html)
BR (1) BR112015005997A8 (cg-RX-API-DMAC7.html)
CA (1) CA2882947A1 (cg-RX-API-DMAC7.html)
ES (1) ES2773105T3 (cg-RX-API-DMAC7.html)
MX (1) MX362517B (cg-RX-API-DMAC7.html)
WO (1) WO2014052171A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101803671B1 (ko) 2013-12-04 2017-11-30 머크 샤프 앤드 돔 코포레이션 역전사효소 억제제의 제조 방법
WO2018175271A1 (en) * 2017-03-24 2018-09-27 Merck Sharp & Dohme Corp. Formulation for parenteral administration
KR20220130698A (ko) * 2019-12-20 2022-09-27 에피자임, 인코포레이티드 Ezh2 억제제의 결정질 하이드로브로마이드 염, 이의 제조 및 암의 치료에 유용한 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309700B2 (en) * 2004-04-02 2007-12-18 Boehringer Ingelheim International Gmbh Crystalline forms of 5,11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2′,3′-e] [1,4]diazepin-6-one
ES2391461T3 (es) * 2004-07-27 2012-11-27 F. Hoffmann-La Roche Ag Compuestos de benciltriazolona utilizados como inhibidores no nucleósidos de transcriptasa inversa
CA2687770C (en) * 2007-05-30 2016-03-08 F. Hoffmann-La Roche Ag Process for preparing triazolones
CN101952274A (zh) * 2007-11-20 2011-01-19 默沙东公司 非核苷逆转录酶抑制剂
MX2012011379A (es) * 2010-03-30 2012-11-30 Merck Canada Inc Inhibidores no nucleosidicos de la transcriptasa inversa.
WO2011126969A1 (en) * 2010-04-08 2011-10-13 Merck Sharp & Dohme Corp. Prodrugs of an hiv reverse transcriptase inhibitor

Also Published As

Publication number Publication date
CN109384765A (zh) 2019-02-26
US20150232447A1 (en) 2015-08-20
EP2900240A1 (en) 2015-08-05
BR112015005997A2 (pt) 2017-07-04
EP2900240B1 (en) 2020-01-08
EP2900240A4 (en) 2016-07-13
WO2014052171A1 (en) 2014-04-03
US9150539B2 (en) 2015-10-06
CA2882947A1 (en) 2014-04-03
JP2018024683A (ja) 2018-02-15
JP2015531372A (ja) 2015-11-02
CN104684557A (zh) 2015-06-03
MX2015003767A (es) 2015-07-14
ES2773105T3 (es) 2020-07-09
JP6387349B2 (ja) 2018-09-05
BR112015005997A8 (pt) 2023-04-11

Similar Documents

Publication Publication Date Title
SA519402405B1 (ar) مركبات مثبط فيروس نقص المناعة البشري
CY1124043T1 (el) Εξουδετερωτικα αντισωματα του ανθρωπινου ιου της ανοσοανεπαρκειας και μεθοδοι χρησης αυτων
MX2015007563A (es) Composiciones farmaceuticas.
NZ598766A (en) Macrocyclic integrase inhibitors
WO2013006688A3 (en) N-terminal deleted gp120 immunogens
CY1118774T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης
MX2009013349A (es) Compuestos quimicos.
MX2013005478A (es) Compuestos heterociclicos condensados antivirales.
EA202191711A1 (ru) Производные пиримидона в качестве селективных цитотоксических агентов против вич-инфицированных клеток
EA201590358A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA201590741A1 (ru) Нейтрализующие анти-вич-антитела широкого спектра действия
EA201000777A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
WO2013132208A8 (en) Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine
GEAP202014873A (en) Methods for treatment and prophylaxis of hiv and aids
EA201101397A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
BR112015005997A2 (pt) composto
WO2009126293A3 (en) Potent chimeric nrti-nnrti bifunctional inhibitors of hiv-1 reverse transcriptase
BR112014003989A2 (pt) composto, composições e métodos para inibir a replicação do hiv-1 em paciente, para tratar pacientes infectados com hiv/aids e para profilaxia de pré-exposição para tratar paciente e para prevenir a transmissão de pessoa infectada para pessoa não infectada
JP2017529355A5 (cg-RX-API-DMAC7.html)
CL2012002743A1 (es) Combinación que comprende maraviroc, un inhibidor de proteasa de vih-1 y un potenciador famacocinetico, uso en la preparacion de un medicamento util en el tratmiento de infeccion por vih.
WO2007098247A3 (en) Substituted taraxastanes useful for treating viral infections
Polo-Megías et al. Potent HIV-1 miniprotein inhibitors targeting highly conserved gp41 epitopes
MX2021014247A (es) Derivados piridinona como agentes citotoxicos selectivos contra celulas infectadas con virus de inmunodeficiencia humana (vih).
WO2008070385A3 (en) Uses of a murine model of hiv-1 infection
MX2016007303A (es) Proceso para preparar inhibidores de la transcriptasa inversa.

Legal Events

Date Code Title Description
FG Grant or registration